Summary of Significant Accounting Policies (Details) (USD $)	1 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended		9 Months Ended			9 Months Ended	1 Months Ended		9 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Jun. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Jul. 30, 2014	Sep. 30, 2014 Initial Warrant [Member]	Sep. 09, 2014 Initial Warrant [Member]	Sep. 09, 2014 SG Financial LLC [Member] Initial Warrant [Member]	Sep. 30, 2014 Subsequent Event [Member]	Jul. 30, 2014 SWK Credit Agreement [Member]	Jul. 31, 2014 SWK Credit Agreement [Member]	Sep. 30, 2014 SWK Credit Agreement [Member]	Sep. 30, 2014 Cost of Goods, Total [Member] Supplier Concentration Risk [Member]	Sep. 30, 2013 Cost of Goods, Total [Member] Supplier Concentration Risk [Member]	Sep. 30, 2014 Cost of Goods, Total [Member] Supplier Concentration Risk [Member]	Sep. 30, 2013 Cost of Goods, Total [Member] Supplier Concentration Risk [Member]	Sep. 30, 2014 Clinical [Member]	Dec. 31, 2013 Clinical [Member]	Sep. 30, 2014 ResponseDX [Member]	Dec. 31, 2013 ResponseDX [Member]
Significant Accounting Policies [Line Items]
Receivable Balance,net allowances for doubtful debts		$ 6,889,100				$ 6,889,100		$ 6,225,923													$ 769,294	$ 1,892,384
Allowance for doubtful accounts		2,204,177				2,204,177		2,404,659															2,204,177	2,404,659
Line of credit, expiration date					Jul. 25, 2016			Mar. 07, 2015					Dec. 31, 2015	Jul. 30, 2020
Line of credit, borrowing base percentage of pharmaceutical accounts receivable					80.00%
Line of credit, interest charged	5.50%			5.00%	5.00%
Line of credit, amount drawn					1,500,000			1,000,000
Advertising costs		26,979	10,924			53,239	14,247
Concentration risk percentage																	76.00%	87.00%	69.00%	90.00%
Payment period from the date of invoice						45 days
Cash and cash equivalents that exceeded federally insured limits		5,826,536				5,826,536
Payments for Fees						40,000
Line Of Credit Facility Fees Payable		10,000				10,000
Loans Receivable, Description of Variable Rate Basis						2.25%
Provision for Doubtful Accounts		1,604,320	688,205			4,266,013	1,506,654
Sales Revenue, Services, Other		547,406	1,550,765			1,724,069	6,200,295
Line of Credit Facility, Initiation Date						Jul. 14, 2011							Feb. 28, 2016
Cash, Uninsured Amount		11,838				11,838
Line of Credit Facility, Maximum Borrowing Capacity									2,000,000					8,500,000
Long-term Debt, Gross														12,000,000
Line of Credit Facility, Interest Rate Description																The Loan bears interest at a rate equal to the LIBOR Rate (as defined in the SWK Credit Agreement) plus an applicable margin of 12.5% per annum, subject to a one percent (1.0%) LIBOR floor. Interest on the Loan is due and payable in arrears (i) on the forty-fifth
Line of Credit Facility, Current Borrowing Capacity														2,500,000
Line of Credit Facility, Commitment Fee Amount													750,000		1,029,412
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											681,090
Warrant Expiration Period										Jul. 30, 2020
Warrant Exercise Price										$ 0.936
Fair value Of Warrants Issued										414,239	414,239
Conversion of Stock Conversion Price Per Share										$ 0.61
Fair Value Assumptions, Risk Free Interest Rate										2.01%
Fair Value Assumptions, Expected Dividend Rate										0.00%
Fair Value Assumptions, Expected Volatility Rate										101.50%
Fair Value Assumptions, Expected Term										6 years
Class of Warrant or Right, Outstanding												200,321
Loans Payable																8,500,000
Debt Issuance Cost																576,161
Adjustments to Additional Paid in Capital, Warrant Issued													0.936			377,140
Deferred Finance Costs, Net																187,092
Line of Credit Facility, Expiration Period													6 years			6 years
Line of Credit Facility, Remaining Borrowing Capacity													$ 3,500,000
Line of Credit Facility, Commitment Fee Percentage													7.50%